Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,723,837
  • Shares Outstanding, K 166,392
  • Annual Sales, $ 726,440 K
  • Annual Income, $ -61,290 K
  • EBIT $ 112 M
  • EBITDA $ 110 M
  • 60-Month Beta 0.38
  • Price/Sales 3.71
  • Price/Cash Flow N/A
  • Price/Book 4.66

Options Overview Details

View History
  • Implied Volatility 40.36% ( -0.28%)
  • Historical Volatility 41.69%
  • IV Percentile 21%
  • IV Rank 26.78%
  • IV High 96.15% on 08/06/24
  • IV Low 19.95% on 09/19/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 114
  • Volume Avg (30-Day) 750
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 24,609
  • Open Int (30-Day) 22,970

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.22
  • Number of Estimates 10
  • High Estimate 0.68
  • Low Estimate -0.07
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.15 +15.69%
on 10/23/24
18.71 -12.51%
on 11/11/24
+1.85 (+12.74%)
since 10/22/24
3-Month
14.15 +15.69%
on 10/23/24
18.71 -12.51%
on 11/11/24
+0.69 (+4.40%)
since 08/22/24
52-Week
14.15 +15.69%
on 10/23/24
32.59 -49.77%
on 12/22/23
-5.62 (-25.56%)
since 11/22/23

Most Recent Stories

More News
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.

ACHC : 38.23 (-0.93%)
NGNE : 20.30 (+30.21%)
ACAD : 16.37 (+1.17%)
TSHA : 2.47 (+13.30%)
Acadia: Q3 Earnings Snapshot

Acadia: Q3 Earnings Snapshot

ACAD : 16.37 (+1.17%)
Do Options Traders Know Something About Acadia (ACAD) Stock We Don't?

Investors in Acadia Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 17, 2025 $3.00 Call had some of the highest...

ACAD : 16.37 (+1.17%)
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?

Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.Auvelity...

JAZZ : 126.67 (+1.25%)
ACAD : 16.37 (+1.17%)
AXSM : 98.68 (+0.50%)
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options

Investors in Acadia Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $29 Call had some of the highest implied...

ACAD : 16.37 (+1.17%)
Acadia: Q2 Earnings Snapshot

Acadia: Q2 Earnings Snapshot

ACAD : 16.37 (+1.17%)
Acadia: Q1 Earnings Snapshot

Acadia: Q1 Earnings Snapshot

ACAD : 16.37 (+1.17%)
Stock Futures Ignore Higher-Than-Expected US Inflation Report

March S&P 500 E-Mini futures (ESH24) are trending up +0.30% this morning as market participants awaited the all-important U.S. consumer inflation report that could shed light on the Federal Reserve’s...

ESH24 : 5,101.67s (-1.01%)
BA : 149.29 (+4.10%)
MRVL : 92.51 (-0.46%)
AMD : 138.35 (+0.63%)
BALY : 17.73 (-0.17%)
WCH.D.DX : 70.760 (-2.10%)
ORCL : 192.29 (-0.07%)
ACAD : 16.37 (+1.17%)
MTN : 184.24 (+1.69%)
HRTG : 12.39 (+0.73%)
CVNA : 259.36 (+4.42%)
Acadia: Q4 Earnings Snapshot

Acadia: Q4 Earnings Snapshot

ACAD : 16.37 (+1.17%)
Acadia: Q3 Earnings Snapshot

Acadia: Q3 Earnings Snapshot

ACAD : 16.37 (+1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 17.38
2nd Resistance Point 17.04
1st Resistance Point 16.70
Last Price 16.37
1st Support Level 16.02
2nd Support Level 15.68
3rd Support Level 15.34

See More

52-Week High 32.59
Fibonacci 61.8% 25.55
Fibonacci 50% 23.37
Fibonacci 38.2% 21.19
Last Price 16.37
52-Week Low 14.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar